A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects with Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Latest Information Update: 15 Jun 2025
At a glance
- Drugs Tarlatamab (Primary)
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms DeLLphi-306
- Sponsors Amgen
Most Recent Events
- 06 Mar 2024 Status changed from not yet recruiting to recruiting.
- 14 Feb 2024 Planned initiation date changed from 31 Jan 2024 to 5 Mar 2024.
- 02 Feb 2024 Planned End Date changed from 15 Oct 2029 to 31 Oct 2029.